Gerald Mancuso, MD
Interventional Cardiology · Kansas City, MONPI 1427012574
Payments from drug & device makers
Across 1,575 payments — averaging $255.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$145K
- Amgen$99K
- Lilly USA, LLC$72K
- Esperion Therapeutics, Inc.$52K
- Amarin Pharma, Inc.$20K
- Boston Scientific$2K
- plus $13K from 50 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$401,779 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Kansas City
- Adnan ChhatriwallaKansas City$3.6M
- James GranthamKansas City$1.6M
- Steven MarsoKansas City$921K
- Matthew BunteKansas City$618K
- Steven LasterKansas City$571K
- Chetan HudedKansas City$513K
- Kenneth HuberKansas City$279K
- Adam SalisburyKansas City$265K
- Anthony HartKansas City$202K
- Bangalore DeepakKansas City$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.